1 Reason Intuitive Surgical (ISRG) Is 1 of the Best Healthcare Stocks You Can Buy Today

Intuitive Surgical (ISRG) shares have seen a 26% decline from recent highs, primarily driven by emerging competitive threats from Medtronic's Hugo RAS system, which is targeting FDA approval for U.S. market entry by early 2026 and has shown success in urologic procedures. Despite this, ISRG maintains a strong competitive position due to high hospital switching costs for its da Vinci systems, which performed 2.68 million procedures in 2024 and expanded its global installed base to 11,040 units. The company projects robust procedure volume growth of 15.5%-17% this year, supporting its current valuation exceeding 55 times earnings, highlighting investor confidence in its durable market leadership despite new entrants.

Analysis

Intuitive Surgical (ISRG) has experienced a significant stock price correction, declining 26% from its recent peak, primarily due to investor concerns over emerging competition from Medtronic's Hugo RAS system. Medtronic has submitted for FDA approval with a potential U.S. market entry targeted for early 2026, following successful results in a urologic procedure study. However, the immediate competitive threat appears contained, as the Hugo system, despite receiving European approval in 2021, has not yet generated sales significant enough for Medtronic to report. Intuitive Surgical's formidable market position is protected by substantial switching costs for hospitals, which invest heavily in both the da Vinci surgical systems and the associated surgeon training. This economic moat is evidenced by the company's expanding footprint, which grew to 11,040 installed systems globally after adding 1,790 units last year, facilitating 2.68 million procedures in 2024. Despite a high valuation of over 55 times forward earnings, the company's own guidance projects robust procedure volume growth of 15.5% to 17% for the current year, suggesting the premium may be justified by its sustained operational momentum and market leadership.

Key Decisions for Investors

• Investors should weigh the company's premium valuation against its strong projected procedure growth of 15.5%-17%, as the recent 26% share price decline may present a more attractive entry point for those with a multi-year investment horizon and high risk tolerance.
• The primary risk to monitor is the market adoption rate of Medtronic's Hugo RAS system, particularly in Europe where it is already approved, as any signs of accelerated market share gain could signal a material shift in the competitive landscape.
• For long-term holders, the analysis reinforces the durability of Intuitive Surgical's business model, suggesting the high switching costs and expanding installed base continue to support the fundamental growth thesis despite near-term stock volatility.